Peeling Back the Onion
Executive Summary
Statistical approaches to looking beneath the surface of the overall market can provide useful insights into the responsiveness of particular products to adjustments in promotional levels. One approach involves examining substantial changes occurring at the level of those physicians exposed to changes in promotion levels for specific products.
You may also be interested in...
The Serendipity of Unintended Experiments
Any promotional increase--including short term ones--that a company makes in one therapeutic category to respond to a marketplace event reverberates through other classes. Contrary to conventional wisdom, even slight and brief shifts in promotional activity can result in significant changes in market share, including in chronic care markets. Companies should observe and bank data from these changes so they can better allocate sales resources when anticipating or reacting to a triggering market event.
How Ochre Bio Bagged Boehringer For Its RNA-Based Regenerative MASH Therapies
UK-based Ochre Bio has signed its first major deal with Boehringer Ingelheim. Scrip talked to its co-founder and CEO, Jack O’Meara, about its human tissue-based drug discovery platform, its resulting RNA platform for liver disease and how the fledgling drug company's early work mirrored that seen in diagnostics.
IGI Bets On Trispecific Antibody To Make Inroads Into Big Pharma Myeloma Turf
Ichnos Glenmark Innovation’s president and CEO talks to Scrip about the promising activity profile of the alliance’s early stage trispecific antibody versus Janssen’s teclistamab and also maintains that the setback for Gilead’s magrolimab hasn’t eclipsed prospects for its bispecific antibody.